HCW Biologics Inc. (HCWB)
2.43
-0.08
(-3.19%)
USD |
NASDAQ |
Sep 09, 10:31
HCW Biologics Debt to Equity Ratio : 0.8834 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.8834 |
| March 31, 2026 | 1.141 |
| December 31, 2025 | 2.463 |
| September 30, 2025 | -3.559 |
| June 30, 2025 | -164.17 |
| March 31, 2025 | -1.628 |
| December 31, 2024 | -2.022 |
| September 30, 2024 | -1.284 |
| June 30, 2024 | -1.591 |
| March 31, 2024 | 0.9467 |
| December 31, 2023 | 0.4793 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.2653 |
| June 30, 2023 | 0.2225 |
| March 31, 2023 | 0.2002 |
| December 31, 2022 | 0.1716 |
| September 30, 2022 | 0.1515 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 26.77M |
| Total Liabilities (Quarterly) | 19.34M |
| Shareholders Equity (Quarterly) | 7.428M |
| Current Ratio | 0.0611 |
| Net Debt Paydown Yield | 18.28% |